5-Amino-1MQ: Mouse Data, No Human Trials & What It Actually Is

Common contexts

• Clinics may reference this peptide within broader wellness or longevity pathways.
• Use this directory page to compare profile transparency and consultation options.

Safety information

• This directory is informational and does not provide medical advice.
• Always discuss suitability and risk profile directly with a licensed clinician.

Clear intro

5-Amino-1MQ is the cleanest example on this site of the mouse-to-marketing pipeline: one genuinely interesting preclinical finding, zero human trials, and a thriving retail market in between. The honest page is short on promises because the evidence is short on humans.

Who this is for

This page is for people who have seen 5-Amino-1MQ in fat-loss stacks or longevity forums and want to know what the evidence actually contains before spending money or taking on unknown risk.

What to ask before choosing a clinic

• No human trials of 5-Amino-1MQ exist — what is the basis for recommending it to me?
• It isn't a peptide — what exactly is the sourcing and quality control for this chemical?
• What approved, evidence-based options address my fat-loss goals first?

Pricing and red flags

Judge any price against this: approved weight-management medicines have Phase 3 evidence in thousands of patients; 5-Amino-1MQ has mice. The gap is not reflected in vendor pricing.

• Human fat-loss or muscle claims stated as fact — no human trial supports them.
• Marketing it as a peptide, or bundling it into 'peptide protocols' without noting it is a different chemical class.
• Confident dosing guidance, which cannot be evidence-based when no human data exists.

What is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme elevated in fat tissue in obesity that consumes NAD+ precursors. Blocking it, the hypothesis goes, should raise cellular NAD+ availability and shift fat-cell metabolism. In obese mice, NNMT inhibition reduced fat mass without changing food intake — a striking result that built the compound's online reputation. What has not happened since is any human trial: as of 2026 there is no completed or registered clinical trial, no published human safety data, no IND, and no approval anywhere. It is also chemically a quinolinium salt, not a peptide — a distinction vendors selling it alongside BPC-157 rarely make.

How it works

The NNMT mechanism is legitimate science with real academic interest — the enzyme sits at a crossroads of NAD+ metabolism and fat-tissue biology. But mechanism plus mouse data is the starting line of drug development, not the finish: most compounds with results this promising in mice fail in humans on efficacy, safety, or both. With 5-Amino-1MQ the human experiment simply has not been run — everyone taking it is running it on themselves, unmonitored.

Cost overview

Whatever it costs, the purchase is an unmonitored self-experiment with a compound lacking any human safety floor. Approved, evidence-based weight-management options exist and make the comparison stark. See the peptide therapy cost guide.

What to expect from clinics

• A credible provider should state plainly that no human trials of 5-Amino-1MQ exist — efficacy and safety in people are unknown.
• Expect acknowledgment that it is not a peptide and sits outside even the loose norms of peptide compounding.
• Any confident dosing protocol is invented — there is no human data from which to derive one.

Safety considerations

There is no published human safety data for 5-Amino-1MQ — no trials, no established dosing, no long-term monitoring in any supervised setting. NNMT sits in fundamental metabolic pathways, and chronic inhibition in humans is an open question. Products are unregulated, so identity and purity are unverified. This page does not recommend 5-Amino-1MQ and does not provide dosing or administration guidance.

Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.